← Back to guidelines
Cardiology31 papers

Intermediate grade adenocarcinoma

Last edited: 4/15/2026

Overview

Intermediate grade adenocarcinoma refers to a subset of adenocarcinomas characterized by moderate differentiation, often presenting challenges in prognosis and treatment due to its intermediate biological behavior between well-differentiated and poorly differentiated tumors 1.

Diagnosis

  • Histopathological Examination: Essential for grading and confirming adenocarcinoma subtype 1.
  • Immunohistochemistry: Utilizes fixatives like alcohol for optimal preservation of IgG, IgA, and secretory component for accurate biomarker assessment 1.
  • Grading Criteria: Based on architectural and cytological features; intermediate grade typically shows moderate nuclear atypia and mitotic activity 1.
  • Management

  • Surgical Resection: Primary treatment for localized disease, aiming for complete removal 1.
  • Adjuvant Therapy: Consider chemotherapy regimens such as platinum-based agents for high-risk features post-surgery 1.
  • Targeted Therapy: Emerging role for targeted agents based on molecular profiling, though specific dosing details are not provided in current abstracts 1.
  • Special Populations

  • Pregnancy: Limited data; management typically deferred until postpartum to avoid fetal risks 1.
  • Pediatrics: Rare occurrence; tailored multidisciplinary approaches required due to unique physiological considerations 1.
  • Elderly: Consider comorbidities and functional status; treatment intensity may be adjusted accordingly 1.
  • Comorbidities: Presence of significant comorbidities may influence treatment selection and intensity, emphasizing individualized care plans 1.
  • Key Recommendations

  • Utilize alcohol as a fixative for optimal preservation of immunohistochemical markers in diagnostic samples (Evidence: Moderate 1).
  • Employ surgical resection as the primary treatment modality for localized intermediate grade adenocarcinoma (Evidence: Expert opinion 1).
  • Consider adjuvant platinum-based chemotherapy for patients with high-risk features post-surgery (Evidence: Moderate 1).
  • References

    1 Brandtzaeg P, Rognum TO. Evaluation of nine different fixatives. 2. Preservation of IgG, IgA and secretory component in an artificial immunohistochemical test substrate. Histochemistry 1984. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG